Novo Nordisk

Aspect Biosystems Ltd. is a biotechnology company based in Vancouver, Canada, focused on 3D bioprinting and tissue engineering. Founded in 2013, it develops bioprinted tissue therapeutics aimed at transforming disease treatment. The company utilizes proprietary microfluidic 3D bioprinting technology to create physiologically relevant living tissues, allowing for precise control over biomaterial composition and structure during fabrication. Aspect Biosystems offers contract testing services using its 3DAirwayALI human tissue model, catering to pharmaceutical firms and academic institutions engaged in research related to respiratory diseases. Through partnerships with leading researchers and industry innovators, the company aims to address significant challenges in regenerative medicine and advance the understanding of human tissue creation for medical research and therapeutic discovery.

Eikonizo Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for neurodegenerative diseases such as Alzheimer's disease and amyotrophic lateral sclerosis. Founded in 2017, the company specializes in creating brain-penetrant small molecules and employs in vivo target engagement techniques to accelerate the discovery of therapeutics. Eikonizo is particularly noted for its selective histone deacetylase 6 inhibitors, which are designed to serve as disease-modifying treatments. By utilizing advanced methodologies, including gene therapy techniques, Eikonizo aims to enhance therapeutic outcomes for patients suffering from debilitating neurological conditions.

Tanai Therapeutics develops novel therapeutics for people living with obesity and obesity-related complications.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a molecular master switch (microRNA) responsible for pathological changes in the heart resulting from stress or injury. By advancing innovative therapies, Cardior Pharmaceuticals aims to address significant health challenges associated with cardiovascular conditions.

Athlone is a provider of culture to art and heritage platform

Biocorp Production specializes in designing, developing, and manufacturing innovative medical devices and drug delivery systems in France. Their product range includes smart caps like Inspair for monitoring inhalers and Mallya for pen injectors, motor-driven devices like Onejet and Datapen, as well as data-collecting devices like Injay. Additionally, they offer pharmaceutical devices such as NEWGUARD for safe needle handling and BIOPASS for reconstitution. Founded in 2004, Biocorp Production is headquartered in Issoire, France.

Embark Biotech is an early-stage biotechnology company based in Copenhagen, Denmark, founded in 2017. The company focuses on identifying novel cell surface receptors that play a significant role in regulating fat tissue calorie-burning and the uptake of glucose and lipids. By offering receptors that stimulate energy expenditure without activating the sympathetic nervous system, Embark Biotech aims to address unmet clinical needs associated with metabolic diseases.

Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative therapies targeting metabolic and fibrotic disorders. The company specializes in peripherally-restricted CB1 receptor inverse agonists, which aim to offer new treatment options for conditions such as Prader-Willi syndrome, diabetes, and related metabolic disorders. Inversago Pharma's research includes addressing complications associated with diabetic kidney disease, non-alcoholic steatohepatitis, and various fibrotic diseases, including interstitial lung disease. Founded in 2015, the company is dedicated to enhancing patient outcomes through its pioneering approach to CB1 blockade.

ElevateBio, LLC is a holding company based in Cambridge, Massachusetts, founded in 2017. It focuses on developing cell and gene therapies for the treatment of cancer and viral infections. The company operates a portfolio of subsidiaries that aim to manufacture and commercialize innovative medicines. ElevateBio collaborates with leading scientists and inventors to create a robust portfolio of therapeutic solutions. Additionally, it has established a centralized facility designed to streamline the translation of cell and gene therapy research into viable medical products, ensuring that patients have access to treatments for severe diseases in a timely manner.

Aspect Biosystems Ltd. is a biotechnology company based in Vancouver, Canada, focused on 3D bioprinting and tissue engineering. Founded in 2013, it develops bioprinted tissue therapeutics aimed at transforming disease treatment. The company utilizes proprietary microfluidic 3D bioprinting technology to create physiologically relevant living tissues, allowing for precise control over biomaterial composition and structure during fabrication. Aspect Biosystems offers contract testing services using its 3DAirwayALI human tissue model, catering to pharmaceutical firms and academic institutions engaged in research related to respiratory diseases. Through partnerships with leading researchers and industry innovators, the company aims to address significant challenges in regenerative medicine and advance the understanding of human tissue creation for medical research and therapeutic discovery.

The Sabi is a community-driven holistic beauty brand that empowers women from conception to postpartum, menopause, and everyday hormonal woes.

Amalgam Rx is the leader in bringing providers, life sciences, and digital solutions together. For more than 15 years, our team has been reimagining care delivery and creating lasting change across the chronic care ecosystem. Working in partnership with many of the world’s leading life sciences companies, Amalgam Rx has built an innovative platform for rapidly developing and scaling digital solutions — delivered through a wide variety of business models. Our proven end-to-end methodology enables the entire life cycle from R&D to commercialization. Amalgam’s solutions have generated more than 5 billion RWE data points utilized by patients and providers on three continents. For more information on how Amalgam Rx’s regulated, clinically validated technologies bring patients and providers closer together, reduce costs for payers, and unlock sustained value for partners, visit amalgamrx.com.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing novel small molecule medicines aimed at treating autoimmune diseases, inflammatory diseases, and cancer by targeting the innate immune system. The company employs a structural immunology platform that provides deep insights into the mechanisms and molecular structures involved in immune responses. This platform integrates proprietary protein engineering capabilities with advanced rational and structure-based drug design tools, allowing for precise targeting of the innate immune system. Ventus is actively building a pipeline of drug programs that address critical targets within this system, particularly proteins involved in inflammasome and nucleic acid-sensing signaling pathways, thereby enabling the treatment of both acute and chronic inflammatory and immune-related conditions.

FORMA Therapeutics is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, specializing in the development and commercialization of innovative therapeutics for rare hematologic diseases and various cancers. The company's notable product candidates include FT-4202, currently in Phase 1 trials for sickle cell disease and other hemoglobinopathies, and FT-7051, which targets metastatic castration-resistant prostate cancer. Additionally, FORMA is advancing FT-2102, an oral investigational agent designed to inhibit mutated IDH1 enzymes, now being evaluated in Phase 2 trials for relapsed/refractory acute myeloid leukemia and exploratory Phase 1 trials for glioma. The company also develops FT-4101 and FT-8225, selective inhibitors of fatty acid synthase. By integrating advanced drug discovery technologies and oncology expertise, FORMA aims to target challenging biological pathways that contribute to cancer, thereby enhancing the development of small molecule drug candidates with unique mechanisms of action.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

Dicerna Pharmaceuticals is a biotechnology company dedicated to the discovery and development of innovative treatments for rare inherited diseases and other conditions affecting the liver. Utilizing its proprietary ribonucleic acid interference (RNAi) technology, specifically the GalXC platform, Dicerna focuses on silencing disease-causing genes to develop pharmaceuticals for various therapeutic areas, including liver diseases, cardiovascular diseases, and cancers. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and additional programs targeting undisclosed rare liver diseases. The company has established strategic collaborations with several major pharmaceutical firms to enhance its research and development efforts. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna Pharmaceuticals aims to address significant unmet medical needs through its innovative approaches.

Glooko is a company that develops a remote patient-monitoring platform specifically designed for individuals with diabetes. This platform integrates with various diabetes devices, fitness wearables, and activity trackers to capture and sync health data. It provides comprehensive reports and analytics aimed at promoting behavior change and improving health outcomes. By enhancing communication between patients and healthcare providers, Glooko facilitates better management of diabetes and supports remote monitoring efforts. The platform is accessible on both Android and iOS devices, allowing users to conveniently track their diabetes-related information on their smartphones.

Emisphere Technologies operates as a pharmaceutical and drug delivery company based in Roseland, New Jersey. The company specializes in utilizing its proprietary Eligen Technology to develop oral formulations of therapeutic agents, focusing primarily on applications for diabetes and related conditions. Its notable product, Eligen B12, is a prescription medical food designed to address vitamin B12 deficiencies without the need for injections. Emisphere is actively engaged in partnerships with major pharmaceutical firms, particularly Novo Nordisk, to create new oral formulations of injectable biopharmaceuticals, including GLP-1 receptor agonists and insulin. The company has a diversified pipeline of product candidates at various stages of development, alongside preclinical programs targeting cardiovascular issues, appetite suppression, and pain management. Emisphere evaluates its development initiatives based on market needs, product differentiation, and potential return on investment. Founded in 1986, the company was previously known as Clinical Technologies Associates, Inc. before its name change in 1991. As of late 2020, it operates as a subsidiary of Novo Nordisk.

Sundew is a biotechnology company founded in 2018 and headquartered in Copenhagen. The company specializes in providing biological services designed to treat aquatic pests and diseases through innovative solutions. Utilizing precision fermentation, Sundew develops environmentally-friendly products aimed at addressing challenges in the aquaculture market, including the management of invasive species and ecological issues such as red tides. By focusing on unmet needs within this sector, Sundew enables its clients to create effective, cost-efficient solutions that are both climate-friendly and sustainable.

Corvidia Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, specializing in the development of precision cardiovascular therapies. Founded in 2014, the company focuses on researching and commercializing innovative treatments for cardio-renal diseases. Corvidia is particularly engaged in developing therapies for chronic kidney disease associated with atherosclerotic cardiovascular disease, inflammation, and high triglyceride-induced acute pancreatitis. As of July 2020, Corvidia operates as a subsidiary of Novo Nordisk A/S, leveraging its expertise to advance its clinical-stage programs aimed at addressing specific biological pathways in patients with unique sensitivities.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

Ziylo Ltd, founded in 2014 and based in Bristol, United Kingdom, specializes in the development of glucose binding molecules (GBMs) aimed at improving the lives of individuals with diabetes. The company focuses on creating a unique class of biomimetic GBMs derived from extensive research in supramolecular chemistry, specifically inspired by nature's carbohydrate-binding molecules known as lectins. These innovative molecules are integral to medical devices like Continuous Glucose Monitors (CGMs) and therapeutics such as Glucose Responsive Insulins (GRIs). Ziylo's technology is founded on over 20 years of research led by Professor Anthony Davis at the University of Bristol. As of August 2018, Ziylo operates as a subsidiary of Novo Nordisk A/S, furthering its mission to enable better glucose management and enhance the quality of life for those living with diabetes.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing innovative immune therapies for cancer treatment. Utilizing its proprietary T-win technology platform, the company creates immune-modulating cancer vaccines that activate T cells specifically targeting immune-suppressive molecules. This approach aims to induce the immune system to disrupt multiple pathways responsible for tumor-induced immunosuppression. IO Biotech has a solid track record in advancing both preclinical and clinical compounds, with its two lead candidates targeting IDO and PD-L1 currently in clinical development, while several additional therapies remain in the preclinical stage.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

MB2 operates in the healthcare industry that focuses on pharmaceutical businesses. It specializes in the fields of therapeutics, healthcare, and pharmaceuticals. MB2 is a U.S.-based company that was founded in 2014. The company was acquired by Novo Nordisk on August 27, 2015.

Calibrium is a privately-held biopharmaceutical company dedicated to the development of innovative drug candidates aimed at treating diabetes and related metabolic disorders. Co-founded by Fritz French, who serves as Chief Executive Officer, and Richard DiMarchi, PhD, the Chief Scientific Officer, Calibrium focuses on creating a diverse portfolio of therapeutic solutions to address the growing challenges posed by these conditions.

Affimed NV is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies. With nearly two decades of expertise in the innate immune system, Affimed aims to provide innovative solutions to enhance cancer treatment outcomes. The company is engaged in the discovery, pre-clinical, and clinical development of antibodies that leverage innate cell engager-based medicines, addressing the limitations of existing immuno-oncology therapies. In addition to its product development efforts, Affimed also generates revenue by offering research and development services to third parties, utilizing both its own and third-party intellectual property.

Osprey Pharmaceuticals USA, Inc. is a clinical-stage biotechnology company based in San Francisco, California, that specializes in developing protein therapeutics aimed at treating inflammatory and immune diseases. Founded in 2008, the company focuses on a pipeline of proprietary fusion protein therapeutics known as Leukocyte Population Modulators (LPMs). These therapeutics are designed to selectively target and neutralize chemokine-activated leukocytes, which play a crucial role in various inflammatory conditions. Osprey's lead candidate, CCL2-LPM, specifically targets the CCR2 chemokine receptor found on pathologically activated leukocytes and is currently undergoing a Phase Ib clinical trial for the treatment of IgA nephropathy, an inflammatory kidney disease.

Xencor, Inc. is a clinical-stage biopharmaceutical company headquartered in Monrovia, California, specializing in the discovery and development of engineered monoclonal antibodies and other protein therapeutics aimed at treating severe and life-threatening diseases. The company leverages its proprietary XmAb technology platform to create a range of antibody product candidates for various conditions, including cancer and autoimmune diseases. Notable candidates in its portfolio include XmAb5871 and AIMab7195, both targeting autoimmune disorders, and several bispecific antibodies currently in clinical trials, such as XmAb14045 for acute myeloid leukemia and plamotamab for B-cell malignancies. Additionally, Xencor is advancing therapies for neuroendocrine tumors and gastrointestinal stromal tumors, as well as developing preclinical bispecific antibodies for various cancers. The company generates revenue through research and development collaborations and licensing agreements with major pharmaceutical firms. Founded in 1997, Xencor is committed to addressing unmet medical needs through innovative therapeutic solutions.

Innate Pharma S.A. is a biotechnology company based in Marseille, France, focused on discovering and developing therapeutic antibodies for oncology and inflammatory diseases. The company is engaged in creating first-in-class immunotherapy drug candidates, leveraging its proprietary platform to harness the innate immune system. Key products in its pipeline include Monalizumab, an immune checkpoint inhibitor in Phase II trials for advanced solid tumors, and Lacutamab, an anti-KIR3DL2 antibody also in Phase II for cutaneous T-cell lymphoma. Additionally, the pipeline features various candidates at different stages, including IPH5201 and IPH5301, which target immunosuppressive pathways. Innate Pharma has established licensing and collaboration agreements with major pharmaceutical companies, enhancing its research and development capabilities. Founded in 1999, the company operates internationally, contributing to the advancement of cancer treatment through innovative therapeutic approaches.

Aldaph SpA manufactures, packages, and markets pharmaceutical products.

TransTech Pharma, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of human therapeutics. The company engages in translating human proteins into medicines for the treatment of various human diseases. Its products include a pipeline of molecule clinical and pre-clinical drug candidates, including antagonists, fusion proteins, activators, inhibitors, agonists, smallpox anti-virals, and thrombosis for the treatment of cardiovascular disorders, central nervous system disorders, inflammatory and infectious diseases, diabetes, obesity, and cancer. TransTech Pharma, Inc. has strategic alliances with Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Merck, Siga Technologies, and Cephalon. The company was founded in 1998 and is based in High Point, North Carolina.

Biobras is a manufacturer and distributor of medical and pharmaceutical products designed for both human and veterinary use. The company produces a variety of dosage forms, including ampoules, tablets, capsules, vials, ointments, powders, and suspensions, catering to both internal and external consumption. Through its diverse product offerings, Biobras aims to meet the healthcare needs of various markets.

ZymoGenetics is dedicated to the discovery, development, and early manufacturing of therapeutic proteins aimed at treating human diseases. As a fully integrated research and development organization, it possesses a diverse array of expertise and technologies, encompassing scientific computing, molecular and cellular biology, protein chemistry, and antibody generation and engineering. The company is actively engaged in advancing a pipeline of therapeutic proteins, including recothrom, which targets hemostasis. ZymoGenetics also covers various aspects of clinical development, regulatory affairs, quality assurance, drug formulation, process development, and protein manufacturing, allowing for a comprehensive approach to therapeutic innovation.